Komori
Pharmarise Holdings (2796) · TargetRestated

Make a Leap 2027 Management Targets for the Fiscal Year Ending May 2028

First written in FY2025. 6 of 7 entries say "Restated". Latest entry: 2026-09-17.

7entries
2years
4from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2025 – 2026-09-172025: 120252026: 62026
Same theme, other companies
Setting and achieving performance targets under the medium-term management planA theme 791 companies write about · 75 as a headwind · 1062 as a tailwind

The whole theme swung hardest in 2021: 17 of 77 companies on the "Worse" side.

31 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 133 companies compared. The sentences above are computed from all 133.Comparing 200 of the theme's 1182 threads.
Full recordFilings, disclosures and news, newest first
  1. 2026-09-17RestatedEarnings

    「For the fiscal year ending May 2028, we aim to achieve revenue of ¥70 billion, operating income of ¥1.6 billion and ROIC of 4.5%.」

    The targets of revenue of ¥70 billion, operating income of ¥1.6 billion and ROIC of 4.5% for the fiscal year ending May 2028 were reiterated.
  2. FY2026RestatedAnnual report

    「For the fiscal year ending May 2028, we aim to achieve revenue of ¥70 billion, operating income of ¥1.6 billion and ROIC of 4.5%.」

    The targets under Make a Leap 2027 for the fiscal year ending May 2028 are reiterated as revenue of ¥70 billion, operating profit of ¥1.6 billion and ROIC of 4.5%.
  4. FY2026-H1RestatedAnnual report

    「For the fiscal year ending May 2028, we aim to achieve revenue of ¥70 billion, operating income of ¥1.6 billion and ROIC of 4.5%.」

    The targets under Make a Leap 2027 for the fiscal year ending May 2028 are reiterated as revenue of ¥70 billion, operating profit of ¥1.6 billion and ROIC of 4.5%.
  5. FY2025First statedAnnual report

    「The consolidated management targets for the fiscal year ending May 2028, the final year of the medium-term management plan, are as follows: revenue of ¥70 billion, operating profit of ¥1.6 billion, net income of ¥700 million and ROIC of 4.5%.」

    The quantitative targets for the fiscal year ending May 2028 under the new medium-term management plan, "Make a Leap 2027: Consolidate the Foundation and Make Further Leaps," were disclosed for the first time.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Pharmarise Holdings's next results are scheduled for 2026-09-17. Read the earnings preview It last moved in the Earnings of 2026-09-17: "Restated".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Make a Leap 2027 Management Targets for the Fiscal Year Ending May 2028 | Pharmarise Holdings Corporation (2796) | Komori